Royalty Pharma (MEX:RPRXN) Common Stock: MXN2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
65 GF Score
Price MXN1,025.44
GF Value MXN559.33
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Common Stock?

Royalty Pharma MEX:RPRXN 65 Common Stock is MXN2 Mil as of Jun. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 65/100 and a GF Value™ of MXN559.33 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's quarterly common stock increased from Dec. 2025 (MXN2 Mil) to Mar. 2026 (MXN2 Mil) but then declined from Mar. 2026 (MXN2 Mil) to Jun. 2026 (MXN2 Mil).

Royalty Pharma's annual common stock increased from Dec. 2023 (MXN2 Mil) to Dec. 2024 (MXN2 Mil) but then declined from Dec. 2024 (MXN2 Mil) to Dec. 2025 (MXN2 Mil).

Royalty Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Common Stock Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only 2.17 2.09 1.83 2.25 1.91

Royalty Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.96 1.91 1.95 1.88
MEX:RPRXN
65GF Score
Royalty Pharma PLC MEX:RPRXN
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of MXN2 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Common Stock of MXN2 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Common Stock too high?
Royalty Pharma's current Common Stock is MXN2 Mil. Overall, Royalty Pharma has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Common Stock compare to ROIV and INCY?
Royalty Pharma's Common Stock of MXN2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Common Stock is MXN2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (MEX:RPRXN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN559.33, compared to a current price of MXN1,025.44 — trading 83.3% above its estimated fair value. The current Common Stock is MXN2 Mil. Royalty Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Common Stock is MXN2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN1,025.44 is trading 83.3% above its estimated GF Value™ of MXN559.33. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for MEX:RPRXN:

  • Common Stock: MXN2 Mil
  • GF Value™: MXN559.33 vs. price of MXN1,025.44 (83.3% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
65GF Score

Get the complete analysis for MEX:RPRXN

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,025.44
Price
MXN559.33
GF Value